Stimulation of N-methyl-D-aspartate (NMDA) receptors on neurons activates both cAMP and cGMP signaling pathways. Experiments were carried out to determine which phosphodiesterase (PDE) families are involved in the hydrolysis of the cyclic nucleotides formed via this mechanism, using primary neuronal cultures prepared from rat cerebral cortex and hippocampus. The nonselective PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) potentiated the ability of NMDA to increase cAMP and cGMP. However, among the family-selective inhibitors, only the PDE4 inhibitor rolipram enhanced the ability of NMDA to increase cAMP in the neurons. In contrast, only the PDE2 inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) enhanced the ability of NMDA to increase cGMP. Neither adenosine nor an adenosine deaminase inhibitor mimicked the effect of EHNA; this suggests that EHNA's inhibition of PDE2, not its effects on adenosine metabolism, mediates its effects on NMDA-stimulated cGMP concentrations. The PDE inhibitoraugmented effects of NMDA on cAMP and cGMP formation were antagonized by 5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801), verifying NMDA receptor mediation. In contrast, only NMDA-mediated cGMP formation was affected by altering either nitric oxide signaling or guanylyl cyclase; this suggests that NMDA-induced changes in cAMP are not secondary to altered cGMP concentrations. Overall, the present findings indicate that cAMP and cGMP formed in neurons as a result of NMDA receptor stimulation are hydrolyzed by PDE4 and PDE2, respectively. Selective inhibitors of the two PDE families will differentially affect the functional consequences of activation of these two signaling pathways by NMDA receptor stimulation.
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N-Methyl-D-aspartate (NMDA) receptors belong to the glutamate receptor family and are ligand-gated ion channels permeable to Ca 2ϩ and Na ϩ ions (Ozawa et al., 1998; Yamakura and Shimonji, 1999) . They are involved in synaptic plasticity, neuronal development, and learning and memory (Collingridge and Lester, 1989; Meldrum and Garthwaite, 1990; Michaelis, 1998) . Long-term potentiation, a cellular mechanism for memory, is regulated in part via NMDA receptor-mediated Ca 2ϩ influx. Activation of the NMDA receptor increases cAMP in the CA1 region of the hippocampus; this increase is mediated through Ca 2ϩ -calmodulin-dependent adenylyl cyclase (Chetkovich et al., 1991; Chetkovich and Sweatt, 1993) . The influx of Ca 2ϩ also stimulates Ca 2ϩ -calmodulin-dependent nitric-oxide (NO) synthase (NOS) type to produce NO, which stimulates guanylyl cyclase to produce cGMP (for review, see Garthwaite, 1991) . The cyclic nucleotides cAMP and cGMP are involved in a number of intracellular processes such as signal transduction, gene transcription, activation of kinases, and regulation of channel function (Burns et al., 1996) . Phosphodiesterases (PDEs) are enzymes that control the intracellular concentrations of cyclic nucleotides by catalyzing their hydrolysis (for review, see Beavo et al., 1994; Conti and Jin, 1999) . Cyclic nucleotide PDEs have been categorized into 11 families and are encoded by at least 21 genes. Additional heterogeneity results from the use of multiple initiation sites and alternative splicing (Beavo et al., 1994; Loughney and Ferguson, 1996) . The PDE families are distinguished by their substrate specificity and characteristic regulation by inhibitors and activators. The major families involved in cGMP hydrolysis are Ca 2ϩ -calmodulin-activated PDE1, cGMP-stimulated PDE2 (K m for cGMP Ͻ cAMP); cGMP-specific PDE5; PDE6, which is unique to photoreceptors; and cGMP-specific PDE9. Cyclic AMP is mainly hydrolyzed by PDE2; cGMP-inhibited PDE3; cAMP-specific PDE4; cAMP-specific, rolipram-insensitive PDE7; cAMP-specific, IBMX-insensitive PDE8; and PDE10 (Conti and Jin, 1999; Soderling and Beavo, 2000) . Rolipram and other PDE4 inhibitors have been shown to have therapeutic efficacy for the treatment of disorders such as depression, asthma, and inflammation (Houslay et al., 1998) . The pharmacological effects of rolipram are linked to its ability to increase cAMP concentrations and activate the corresponding signal transduction cascade. Some studies suggest that rolipram may alter NMDA receptor-mediated signaling. In rat retrospenial cortex, MK-801, a noncompetitive NMDA receptor antagonist, induces heat shock protein HSP-70, a marker for reversible neuronal damage. Rolipram, which selectively inhibits PDE4 and leads to an increase in cAMP, reverses the effect of MK-801 on HSP-70 expression (Hashimoto et al., 1997) . In Mongolian gerbils, neuronal death due to cerebral ischemia, a process that seems to involve NMDA receptors, is prevented by pretreatment with rolipram (Kato et al., 1995) . This suggests a role for PDE4 in neurotoxic effects of NMDA receptor antagonists and cerebral ischemia. It also has been shown that chronic treatment with rolipram increases [
3 H]MK-801 binding in the dentate gyrus of both young and aged rats (Kato et al., 1997) . Recent behavioral studies have shown that the memory impairments induced by MK-801 are antagonized by rolipram (Zhang et al., 2000) . Finally, PDE4 inhibitors have been found to potentiate the ability of NMDA to increase cAMP in hippocampal slices and neuronal cultures (Chetkovich and Sweatt, 1993; Zhang et al., 2000) . Overall, these data suggest that PDE4 is involved in NMDA receptor-mediated signaling; however, potential roles for other PDE families in this signaling pathway have not been investigated.
In cultured cerebellar granule cells, NO donors and NMDA induce cGMP formation; this effect is potentiated by IBMX, a nonselective PDE inhibitor (Baltrons et al., 1997; Oh et al., 1997) . Immunocytochemical studies done in cerebellar slice preparations also have shown potentiation by IBMX of NOdependent cGMP formation in granule neurons (de Vente et al., 1990; Southam et al., 1992) . These studies suggest that PDEs are regulators of cGMP in neurons; however, it is not clear which PDE families are involved in the hydrolysis of cGMP formed by NMDA receptor stimulation.
The present study was conducted to identify the PDE families involved in NMDA receptor signaling. Cultures of rat cerebral cortical and hippocampal neurons were used to evaluate the effects of PDE inhibitors on NMDA receptor-mediated cAMP and cGMP formation. It was found that the PDE4 and PDE2 families regulate the NMDA receptor-mediated cAMP and cGMP concentrations, respectively.
Experimental Procedures
Animals. Timed pregnant Sprague-Dawley rats were purchased from Harlan (Indianapolis, IN). The rats were housed individually in a climate-controlled environment on a 12-h light/dark cycle with free access to food and water.
Drugs and Chemicals. Dulbecco's modified Eagle's medium (DMEM), penicillin G, streptomycin, and amphotericin B (Fungizone) were purchased from Invitrogen (Carlsbad, CA). Poly-L-lysine, DNase, and plasma-derived horse serum (PDHS) were purchased from Sigma-Aldrich (St. Louis, MO). Trypsin was purchased from Worthington Biochemicals (Freehold, NJ), 35-mm NUNC tissue culture dishes were purchased from VWR (Willard, OH), and BCA protein assay kits were purchased from Pierce Chemical (Rockford, IL). Tetrodotoxin (TTX) was purchased from Alexis and Calbiochem (San Diego, CA); milrinone, vinpocetine, adenine (EHNA) were purchased from Sigma/RBI (Natick, MA). 1H-[1,2,4]Oxadiazolo[4, 3-a] quinoxalin-1-one (ODQ) and rolipram were purchased from Tocris Cookson (Ballwin, MO) . N -Nitro-L-arginine methyl ester (L-NAME), (S)-p-nitrobenzyl-6-thioinosine (NMBPR), NMDA, diethylamine nanoate (DEA/NO), and adenosine were purchased from Sigma-Aldrich.
Preparation of Neuronal Cultures from Cerebral Cortex. Newborn rat pups were anesthetized with pentobarbital and their cerebral cortices were dissected and placed in an isotonic salt solution containing 100 units of penicillin G, 100 g of streptomycin, and 25 g of amphotericin B (Fungizone) per milliliter, pH 7.4 (Chandler et al., 1997) . The pia mater and the blood vessels were cleaned from the cortices, which were then chopped into pieces and incubated in 4 ml of an isotonic salt solution containing 0.25% trypsin (w/v) in a shaking water bath at 37°C for 10 min. The reaction was stopped by the addition of 4 ml of 0.016% DNase, and further incubation was carried out in a water bath for 5 min. After incubation, regular DMEM (with 10% PDHS) was added, and the cells were triturated to dissociate them. The cell suspension was then centrifuged at 600g for 10 min at 24°C. The supernatant was aspirated and the pellet was resuspended in regular DMEM and plated onto poly-L-lysine-coated culture dishes at a density of 3 ϫ 10 6 cells/35-mm dish. The dishes were then incubated at 37°C in a 5% CO 2 , 95% O 2 atmosphere. On day 3, the media were replaced with fresh DMEM containing 10 M ␤-cytosine arabinoside to diminish glial cell proliferation. On day 5, the ␤-cytosine arabinoside-containing media were aspirated, and regular DMEM was added to the cells. The cells were grown for seven more days before they were used for experiments (day 12).
Preparation of Neuronal Cultures from Hippocampus. A modification of the procedure described above was used for the preparation of hippocampal cultures. In brief, the hippocampus was dissected, chopped into pieces, and incubated with 2 ml of 0.25% trypsin (w/v) in a 37°C water bath for 10 min. The reaction was stopped by addition of 2 ml of 0.016% DNase, followed by trituration four to five times with a fire-polished pipette and a 5-min incubation at 37°C. The supernatant was transferred to a tube containing 20 ml of DMEM/PDHS, and the trypsin treatment was repeated two more times. The procedure for the cortical cultures was then followed and the cells were plated at a density of 1 ϫ 10 6 cells/35-mm dish. The neurons were maintained similarly to the cortical cultures and were used for experiments on day 12.
Treatment of Cultures. The cells were rinsed and incubated for 50 min at 37°C in HEPES buffer (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 100 nM glycine, 15 mM glucose, and 25 mM HEPES, pH 7.4) containing 1 M TTX. Antagonists and inhibitors . N -Nitro-L-arginine methyl ester, ODQ, or adenosine was added 10 min before the addition of NMDA. The NO donor DEA/NO was added 2 min before NMDA. Fifteen minutes after the addition of NMDA, the cells were scraped into 100 l of ice-cold 0.4 N perchloric acid, homogenized, and centrifuged at 21,000g for 30 min at 4°C. After neutralization, the supernatant was used for cAMP or cGMP determinations; the pellet was homogenized in 100 l of 1 N NaOH, and the protein content was determined using the bicinchoninic acid assay (Smith et al., 1985) .
Measurement of cAMP and cGMP. cAMP and cGMP in the hippocampal and cerebral cortical neuronal samples were measured by radioimmunoassay (PerkinElmer Life Sciences, Boston, MA; Zhang et al., 2000) . cAMP and cGMP were normalized to the protein content for each sample.
Statistical Analysis. Data are presented as means Ϯ S.E. expressed as a percentage of control (i.e., TTX-treated samples); experimental data were normalized to control data obtained from the same jpet.aspetjournals.org preparation of neurons. Due to heterogeneous variability the statistical analysis were performed on log-transformed values. Data were analyzed using one-way ANOVA with repeated measures and the Newman-Keuls post hoc test. Wherever appropriate, two-way ANOVA was used. Student's t tests were used for some a priori comparisons.
Results
NMDA Receptor-Mediated Increase in cAMP and cGMP. Cerebral cortical cultures were preincubated with buffer containing 1 M TTX to reduce synaptic activity that could alter cAMP or cGMP concentrations; data are presented as percentage of the TTX control values. Control cAMP and cGMP concentrations in neurons prepared from cerebral cortex averaged 0.75 and 0.05 pmol/mg of protein, respectively. In the presence of NMDA (30 M) only, the cGMP, but not cAMP, concentration was elevated (Fig. 1) . IBMX (0.5 mM), a nonselective PDE inhibitor, slightly increased cAMP and cGMP. However, in the presence of IBMX and NMDA, cAMP and cGMP were increased to approximately 600 and 3500% of control, respectively.
PDE4 Family Regulates NMDA Receptor-Mediated Increase in cAMP. To investigate which PDE family hydrolyzes cAMP formed by NMDA receptor stimulation, NMDA concentration-effect curves were determined in the presence of family-selective PDE inhibitors (Fig. 2) . No effects on cAMP were observed when the neurons were treated with 10 M concentrations of vinpocetine (PDE1), EHNA (PDE2), milrinone (PDE3), or zaprinast (PDE5), either alone or in the presence of NMDA. NMDA receptor-mediated increases in cAMP were observed only when the cultured neurons were pretreated with a 10 M concentration of the PDE4 inhibitor rolipram (Fig. 2D) . NMDA (30 M) produced the largest increase in cAMP in the presence of rolipram; this concentration of NMDA was used for further experiments. Overall, these data suggested that PDE4 is the major regulator of cAMP formed by stimulation of NMDA receptors in cerebral cortical neurons.
The effects of different concentrations of rolipram (10 Ϫ8 -10 Ϫ3 M) on NMDA receptor-mediated cAMP concentrations were determined (Fig. 3) . NMDA alone did not increase cAMP. Significant increases in cAMP were observed in neurons treated with 10 M rolipram in the presence of NMDA (30 M), compared with rolipram alone. There was no significant difference between the other concentrations of rolipram alone versus the presence of NMDA; however, overall, there was a strong tendency toward increased cAMP at the other rolipram concentrations tested (p ϭ 0.06 for rolipram ϫ NMDA interaction).
MK-801 Antagonizes Effect of NMDA and Rolipram on cAMP. To confirm the role of NMDA receptors in mediating NMDA-induced increases in cAMP, antagonism studies were carried out using MK-801, a noncompetitive antagonist. In cerebral cortical cultures, NMDA (30 M) significantly increased cAMP only in the presence of 10 M rolipram ( Fig.  4A ; p Ͻ 0.01). This effect was antagonized by 10 M MK-801 (p Ͻ 0.01 versus NMDA ϩ rolipram). MK-801, either alone or in the presence of NMDA, did not affect cAMP (98 Ϯ 8 and 121 Ϯ 20% of control, respectively).
In hippocampal cultures, control cAMP concentrations averaged 0.72 pmol/mg protein. There was a significant increase in cAMP in the presence of NMDA and 10 M rolipram ( Fig. 4B ; p Ͻ 0.01 versus NMDA or control); MK-801 attenuated this effect (p Ͻ 0.05 versus NMDA ϩ rolipram).
PDE2 Family Regulates NMDA Receptor-Mediated Increase in cGMP. Cerebral cortical cultures were treated with NMDA (30 M), either alone or in the presence of 10 M concentrations of PDE inhibitors. NMDA increased cGMP to 400% of control (Fig. 5) . The PDE inhibitors vinpocetine, milrinone, rolipram, and zaprinast did not produce any significant effects on cGMP when used alone and did not potentiate the effect of NMDA on cGMP. Dipyridamole (inhibitor of PDE5, PDE7, PDE8, PDE10, and PDE11) modestly enhanced the effects of NMDA on cGMP, but had no effect An EHNA concentration-response curve for the potentiation of NMDA receptor-mediated cGMP formation was determined using neuronal cultures prepared from rat cerebral cortex (Fig. 6) . NMDA alone increased cGMP concentrations; this effect was potentiated by EHNA in a concentrationdependent manner.
MK-801 Antagonizes Effects of NMDA and EHNA on cGMP. In cerebral cortical cultures, combined treatment with NMDA and EHNA increased cGMP to greater than 2000% of control. This effect was completely antagonized by MK-801 (Fig. 7A) . Qualitatively similar effects were obtained using primary neuronal cultures prepared from hippocampus ( Fig. 7B ; control cGMP concentrations averaged 0.004 pmol/mg of protein). Effect of Adenosine on cGMP. Because EHNA is also an adenosine deaminase inhibitor, experiments were conducted to rule out a role for adenosine in the effects described above.
Cerebral cortical neurons were treated with 10 M adenosine or NMBPR, an adenosine uptake inhibitor, in the presence or absence of NMDA (30 M). Adenosine or NMBPR did not affect cGMP (113 Ϯ 50 and 85 Ϯ 45% of control, respectively; Fig. 8 ). Neither adenosine nor NMBPR enhanced the effects of NMDA on cGMP (101 Ϯ 20 and 199 Ϯ 99% of control, respectively). In contrast, EHNA significantly increased cGMP in the presence of NMDA (p Ͻ 0.01). 
Downloaded from
Effects of NO Donor and NOS Inhibitor on cAMP and cGMP. Potential interactions between the NMDA/NO/cGMP pathway and the NMDA/cAMP pathway were examined. The NOS inhibitor L-NAME (100 M) did not affect cAMP, either alone or in presence of 30 M NMDA (131 Ϯ 41 and 96 Ϯ 27% of control, respectively; data not shown). L-NAME alone did not affect cGMP (68 Ϯ 9% of control; Fig. 9 ). NMDA produced a significant increase in cGMP (p Ͻ 0.01 versus control), and this effect was antagonized by pretreatment with L-NAME (p Ͻ 0.01 versus NMDA). DEA/NO (1 M), an NO donor, did not affect cAMP (68 Ϯ 12% of control; data not shown), whereas DEA/NO significantly increased cGMP (p Ͻ 0.01 versus control; Fig. 9 ). These data suggest that NMDA receptor-stimulated NO production is required for activation of guanylyl cyclase, and there is no direct interaction between the cGMP and the cAMP pathways.
Effect of a Guanylyl Cyclase Inhibitor on cAMP and cGMP. Cerebral cortical neurons were treated with ODQ, an NO-selective guanylyl cyclase inhibitor. ODQ (0.3 or 1 M) alone did not affect cAMP (84 Ϯ 30 and 108 Ϯ 17% of control, respectively; data not shown) nor did it alter the effects of NMDA on cAMP. No changes were produced in cGMP in the presence of ODQ (0.3 or 1 M) alone (81 Ϯ 13 and 89 Ϯ 42% of control, respectively; Fig. 10 ), but ODQ (0.3 and 1 M) did block the NMDA-induced increase in cGMP concentrations (p Ͻ 0.01 versus NMDA).
Discussion
Selective inhibitors of PDE4 and PDE2 enhanced NMDA receptor-mediated cAMP and cGMP formation, respectively, in rat cerebral cortical and hippocampal neurons. The NMDA receptor-mediated increase in cAMP was observed only in the presence of the PDE4 inhibitor rolipram. This is consistent with a previous study, which showed that rolipram reverses the amnesic effects of MK-801 and augments NMDA-induced increases in cAMP formation (Zhang et al., 2000) . The PDE4 family is the major regulator of cAMP concentrations in many cell types. In cultured cortical neurons, ␤-adrenergic receptor-stimulated cAMP concentrations are predominantly controlled by the PDE4 and PDE2 families (Yamashita et al., 1997) . However, in the present study, EHNA, which is a PDE2 inhibitor, did not enhance NMDA receptor-mediated cAMP formation. The roles of other PDEs were examined using 10 M concentrations of the family-selective inhibitors vinpocetine (PDE1), milrinone (PDE3), and zaprinast (PDE5); previous work has shown these inhibitors to be effective at this concentration (Hagiwara et al., 1984; Komas et , 1996; Silver, 1996) . None of these inhibitors had any effects on cAMP either alone or in the presence of NMDA.
Although only inhibitors of PDE2 and PDE4 affected NMDA receptor-mediated cyclic nucleotide signaling, other PDE families, including those examined pharmacologically in the present study, are expressed in the brains of various species (Loughney and Ferguson, 1996; Cherry and Davis, 1999; Cho et al., 2000; Perez-Torres et al., 2000; Giordano et al., 2001; van Staveren et al., 2001) . At least one variant of each of these families is found in cerebral cortex and hippocampus. The association of PDE2 and PDE4 with NMDA receptor-mediated signaling is consistent with a previous suggestion that PDE enzymes are targeted to particular cellular processes (Houslay et al., 1998) .
Studies examining the CA1 region of the hippocampus have shown that NMDA increases cAMP via a Ca 2ϩ /calmodulin-dependent adenylyl cyclase (Chetkovich et al., 1991; Chetkovich and Sweatt, 1993) . In the present study, the NMDA receptor-mediated increases in cAMP in hippocampal cultures were observed only in the presence of the PDE4 family-selective inhibitor rolipram; this effect was attenuated by MK-801. Overall, these data suggest that in cerebral cortical and hippocampal cultures, PDE4 tightly regulates cAMP formed by stimulation of NMDA receptors.
Previous studies have shown PDEs to be very efficient regulators of cGMP concentrations in hippocampal neurons (Greenberg et al., 1978; Vallebuona and Raiteri, 1994) . In cultured cerebellar granule cells and astroglia, NMDA enhances cGMP concentrations in the presence of the nonselective PDE inhibitor IBMX (Baltrons et al., 1997) . This is consistent with the present studies using cultured cerebral cortical neurons, where IBMX enhanced NMDA receptormediated cGMP formation. In hippocampal and cerebral cortical cultures, EHNA and NMDA alone produced only modest increases in cGMP. However, EHNA, which had no effects on NMDA receptor-mediated cAMP concentrations, enhanced the effect of NMDA on cGMP formation. To the extent that they can be examined pharmacologically, it seems that the PDE families other than PDE2 and PDE4 are not involved in regulation of NMDA receptor-mediated cyclic nucleotide levels.
Cyclic nucleotide pathways can cross talk to modulate each other's synthesis, degradation, and actions. Increased cGMP can increase the activity of cGMP-stimulated PDE2 to enhance hydrolysis of cAMP, or it can inhibit the PDE3 family and decrease the hydrolysis of cAMP (Pelligrino and Wang, 1998) . However, in the present study, neither the PDE2 nor the PDE3 family affected cAMP hydrolysis. Although there was an increase in cGMP in the presence of the PDE2 inhibitor and NMDA, it did not affect the hydrolysis of cAMP formed by stimulation of NMDA receptors. A previous study has shown that forskolin, an activator of adenylyl cyclase, inhibits PDE5 and PDE1 via activation of protein kinase A, repressing cGMP degradation in pial arterioles of rats (Pelligrino and Wang, 1998) . However, in the present study, the increase in cAMP in the presence of NMDA and rolipram did not lead to corresponding changes in cGMP concentrations. Thus, in the neuronal cultures, there does not seem to be a direct interaction between cAMP and cGMP pathways associated with NMDA receptor-mediated signaling.
There are reports that PDE4, although it is a cAMP-specific PDE, regulates the hydrolysis of cGMP in certain cell types. In hippocampal slices exhibiting high intracellular concentrations of cGMP, PDE4 contributes to the hydrolysis of cGMP (van Staveren et al., 2001) . In cerebellar granule cells, PDE4 is involved in the hydrolysis of NO-dependent cGMP without altering cAMP levels (Bellamy and Garthwaite, 2001 ). In bovine endothelial cells, the rolipram-induced increase in cAMP has been shown to enhance an Larginine-induced increase in cGMP (Kessler and Lugnier, 1995) . In the present study, rolipram alone did not increase cAMP or cGMP in cerebral cortical or hippocampal neurons. The increase in NMDA receptor-mediated cGMP concentrations was not under the hydrolytic regulation of PDE4, either directly or secondarily due to an increase in cAMP.
To confirm the role of NO in NMDA receptor-mediated signaling, the effects of DEA/NO, an NO donor, and L-NAME, an NOS inhibitor, were tested. NMDA receptor activation involves NO because L-NAME significantly attenuated the effects of NMDA on cGMP. This is consistent with previous studies, which have shown the relevance of NO in glutamate receptor-mediated signaling (for review, see Garthwaite, 1991) . This further confirms that the NMDA effect on cGMP is not due to an indirect effect of cAMP via guanylyl cyclase. Some studies have shown that EHNA increases cGMP in cortical neurons with or without the stimulation of NO-dependent guanylyl cyclase (Yamashita et al., 1997) . However, in the present study, it was found that ODQ, an NO-selective guanylyl cyclase inhibitor, blocked the effects of NMDA on cGMP. This confirms that the NMDA/NO/guanylyl cyclase pathway is involved in the production of cGMP in cerebral cortical cultures.
It does not seem that the ability of EHNA to inhibit adenosine deaminase was involved in its effects on NMDA-stimulated cGMP formation. Dipyridamole, an inhibitor of multiple PDE families that also inhibits adenosine deaminase, only modestly potentiated the ability of NMDA to increase cGMP concentrations. Furthermore, NMBPR, an adenosine uptake inhibitor, and adenosine did not affect cGMP, either in the presence or absence of NMDA.
Recent studies have shown the compartmentalization of PDEs along with components of signal transduction cascades. PDE4D5 has been shown to associate with RACK1, a scaffolding protein for protein kinase C (Yarwood et al., 1999) . RACK1 does not associate with the other PDE4D variants or with other PDE4 subtypes. PDE4D3 and protein kinase A have been found to coexist in a complex through their association with mAKAP, a muscle-selective A-kinase anchoring protein, where they are thought to regulate cAMP signaling (Dodge et al., 2001) . There are no published data concerning the compartmentalization of the PDE2 family. NMDA receptors are expressed along with kinases and anchoring proteins in the postsynaptic density on neurons (Suen et al., 1998) . Because the PDE4 and PDE2 families tightly regulate NMDA receptor signaling, it is possible that these PDEs might exist in a complex with the other components of the NMDA receptor signaling complex.
The present work suggests that both cAMP and cGMP are involved in NMDA receptor-mediated signaling in cerebral cortical and hippocampal neuronal cultures. The influx of Ca 2ϩ via the NMDA receptor stimulates calcium/calmodulindependent adenylyl cyclase, leading to production of cAMP. This increase in cAMP seems to be tightly regulated by PDE4. The Ca 2ϩ influx also stimulates the production of NO and subsequent activation of guanylyl cyclase, leading to cGMP production. PDE2 hydrolyzes cGMP formed by this mechanism. These data suggest that the functional consequences of these two aspects of NMDA receptor-mediated signaling may be differentially affected by PDE2 and PDE4 inhibitors.
